Clinical Trials
Vitreoretinal Consultants of NY is nationally recognized for research and clinical trials related to age-related macular degeneration, diabetic eye complications, and more. Not only do clinical trials play a pivotal role in the development of new and improved treatment modalities, but they also provide eligible patients with access to zero-cost retinal care. Below is a list of active trials that are currently available for enrollment, as well as a list of previous trials. For more information on our clinical trials and how to enroll, contact us today.
For more information or to inquire about clinical trials at VRC, please contact Kristen D'Amore at 516-466-0390 ext. 222.
DR: NPDR
A Multicentre, randomised, sham controlled (and activate conrolled in the USA), double masked, 72- week trial to study the saftey, tolerability, pharmacokinetics, and efficacy of 3 dosing regimns of inatrivals BI 764524 in patients with monderate to severe non-proliferative diabetic retinopathy.
Boehringer Ingelheim Pharmaceuticals, Inc. 1436-0007 (CRIMSON)
DME: Diabetic Macular Edema
GR43828 | A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered With Aflibercept in Patients With Diabetic Macular Edema.
Genentech, Inc. GR43828 (THAMES)
DME: Diabetic Macular Edema
A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema.
Eyebiotech, Ltd. EYE-RES-103 (BAROLO)
DME: Diabetic Macular Edema
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME).
EyePoint Pharmaceuticals, Inc. EYP-1901-303 (COMO)
Dry AMD: Geographic Atrophy
AB38944-A Prospective, Multicenter, Open-Label, Observ Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Apellis Pharmaceuticals, Inc. APL2-GA-411 (GARLAND)
Dry AMD: Geographic Atrophy
Phase 3, Multicenter, Randomized, Double- Masked, Placebo controlled study of Tinlarebant to explore safety and Efficady in the treatment of Geographic Atrophy.
Belite Bio, Inc. LBS-008-CT05 (PHOENIX)
Dry AMD: Geographic Atrophy
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
Annexon, Inc. ANX007-GA-02 (ARCHER II)
Dry AMD: Geographic Atrophy
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD).
ONL Therapeutics, Inc. ONL1204-GA-002 (GALAXY)
Dry AMD: Geographic Atrophy
A non-interventional, observational study to evaluate treatment patterns and safety of avacincaptad pegol (ACP/IZERVAY™) in routine clinical practice in patients with geographic atrophy secondary to age-related macular degeneration.
Astellas, 3021-MA-3543
Dry AMD: Geographic Atrophy
A Phase 2, Randomized, Placebo-Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Apellis Pharmaceuticals, Inc. APL3007-GA-201 (GALLOP)
IRD: Retinitis Pigmentosa
A Randomized, masked, sham-controlled phase 2 trial of the safety of asingle intravitreal injection of JCELL (Famzeretcel) for the treatment of Retinitis Pigmentosa (RP).
jCyte, Inc. JC02-88
IRD: Stargardts Disease
A Phase 2/3 Randomized, Double-Masked, and Placebo controlled study to evaluate the safety, tolerability and efficacy of Tilareabant in subjects with Stargardt Disease
Belite Bio, Inc. LBS-008-CT07 (DRAGON 2)
IRD: Stargardts Disease
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo Controlled Study to Investigate Long-Term Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD1)
EyePoint Pharmaceuticals, Inc. ALK001-P1004 (TEASE)
IRD: Stickler Syndrome
Ora Secunda Cerclage Laser Retinopexy to Prevent Retinal Detachment in Stickler Syndrome (OSC/SS): A Prospective Historically Controlled Study.
Neovascular AMD (naïve or previously TX)
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD.
EyePoint Pharmaceuticals, Inc. EYP-1901-302 (LUCIA)
Neovascular AMD (naïve or previously TX)
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2).
4D Molecular Therapeutics, Inc. 4D-150-C004 (4FRONT-2)
Neovascular AMD (TX Naïve)
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK.
Kodiak Sciences Inc. KS301P109 (DAYBREAK)
Neovascular AMD (TX Naïve)
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration.
Amgen, Inc. 20250115
Neovascular AMD (TX Naïve)
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared with Intravitreal Aflibercept (2mg) in Participants with Neovascular Age-Related Macular Degeneration (NVAMD).
Eyebiotech, Ltd, MK-8748-002 (Malbec)
Neovascular AMD (TX Naïve)
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared with Intravitreal Aflibercept (2mg) in Participants with Neovascular Age-Related Macular Degeneration (NVAMD)
Eyebiotech, Ltd, MK-8748-003 (TORRONTES)
Other: nAMD & DME
A Phase 3B Single-Arm Study of Aflibercept 8 mg in Participants with Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, VGFTe-HD-OD-2444 (ELARA)
